July 20, 2005

Advair, Serevent, and Foradil to remain on the market

Filed under: Medicine

As a followup to last Wednesday’s post the panel assembled to ascertain whether or not Serevent, Advair, and Foradil should remain on the market voted unanimously to keep the three drugs available, citing an acceptable risk/benefit ratio. The panel also did not recommend any changes to the products or their packaging. This is good news for the estimated 20 million asthma sufferers in the United States.

Comments (0) | 10:03 am |

No Comments »

No comments yet.

RSS feed for comments on this post. | TrackBack URI
You can also bookmark this on del.icio.us or check the cosmos

Leave a comment

XHTML ( You can use these tags): <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> .

« Bullets: Stress, Computer games, IQ, &c…    Duragesic under the microscope »